|drug1245||High Flow Nasal Oxygen (HFNO) Wiki||1.00|
|drug1233||Helmet Continuous Positive Airway Pressure (CPAP) Wiki||1.00|
|D011024||Pneumonia, Viral NIH||0.12|
|D045169||Severe Acute Respiratory Syndrome NIH||0.05|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
The purpose of this research study is to evaluate and improve a rapid COVID-19 test. The test is designed to identify people who are most contagious and likely to spread the virus to others. This test will be performed at various locations in the Madison area (including workplaces and schools) using a mobile laboratory. Saliva samples will be collected and processed at these locations with results of positive tests being communicated to the participants by a healthcare worker on the study team. Individuals with a positive test result will be encouraged to self isolate and discuss obtaining a diagnostic test at their earliest convenience.
Description: Feasibility is determined when at least 1000 samples are tested and consistently shown that the assay can detect SARS-CoV-2 safely, consistently and accurately at multiple locations using the mobile laboratory. This is further defined as >99% specificity and >99% sensitivity to detect samples with viral loads consistent with live virus shedding, defined as a PCR Ct > 30 or 1 million viral copies / mL.Measure: Number of Samples Tested Consistently and Accurately per Protocol Time: up to 90 minutes
Description: Feasibility is determined when at least 1000 samples are tested and consistently shown that the assay can detect SARS-CoV-2 safely, consistently and accurately at multiple locations using the mobile laboratory. This testing protocol will be considered safe if COVID-19 rates of those performing the tests do not significantly exceed those of the communities in which the tests are being performed.Measure: Safety: COVID-19 rates of Investigators vs Communities tested Time: up to 2 months